Neuromyelitis Optica: Clinical Trials

25 trials for Neuromyelitis Optica, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 5 active not recruiting, 5 recruiting, 4 terminated. 25 Phase 3, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 325Completed 8, Active not recruiting 5, Recruiting 5, Terminated 4, Not yet recruiting 1, Unknown 1, Withdrawn 1
Phase 28Completed 3, Active not recruiting 2, Recruiting 1, Terminated 1, Withdrawn 1

Follow Neuromyelitis Optica: new trials by email Literature Review of Neuromyelitis Optica trials Research Report on Neuromyelitis Optica

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder
Phase 3RecruitingAlexion Pharmaceuticals, Inc.192026-07-202026-09-11
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Satralizumab - Neuromyelitis Optica Spectrum Disorder, NMOSD
Phase 3RecruitingHoffmann-La Roche82026-05-062026-10-01
Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Eculizumab administration, High-dose corticosteroid pulse therapy, Plasma exchange (PE) - Neuromyelitis Optica Spectrum Disorders (NMOSD)
Phase 3RecruitingTianjin Medical University General Hospital1982026-01-012026-05-14
Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD
Slow-tapering glucocorticoids + Inebilizumab, Rapid-tapering glucocorticoids + Inebilizumab - Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD)
Phase 3Not yet recruitingTianjin Medical University General Hospital1702025-09-012025-08-20
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
eculizumab - NMOSD, Neuromyelitis Optica Spectrum Disorders
Phase 3Active not recruitingAlexion Pharmaceuticals, Inc.212025-01-162025-12-19
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
B001, Placebo - Neuromyelitis Optica Spectrum Disorders
Phase 2 / Phase 3RecruitingShanghai Jiaolian Drug Research and Development Co., Ltd1322024-07-172026-05-05
Azathioprine in MOGAD
Azathioprine, Placebo - Central Nervous System Inflammation, MOG-IgG Associated Disease
Phase 3RecruitingHospices Civils de Lyon1262023-12-122025-02-04
Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
divozilimab - Neuromyelitis Optica Spectrum Disorders
Phase 3Active not recruitingBiocad1052022-12-122024-11-07
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
Daratumumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Phase 2 / Phase 3Active not recruitingTianjin Medical University General Hospital1352022-11-012025-03-30
A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
MIL62, Placebo - Neuromyelitis Optica Spectrum Disorder
Phase 3Active not recruitingBeijing Mabworks Biotech Co., Ltd.1022022-08-182025-09-25
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Ravulizumab - Neuromyelitis Optica Spectrum Disorder
Phase 2 / Phase 3Active not recruitingAlexion Pharmaceuticals, Inc.122022-06-232026-06-24
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF) - Neuromyelitis Optica Spectrum Disorder
Phase 3CompletedHoffmann-La Roche1192021-03-022024-12-27
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Phase 2 / Phase 3TerminatedAlexion Pharmaceuticals, Inc.52020-01-142024-09-25
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Ravulizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Phase 3CompletedAlexion Pharmaceuticals, Inc.582019-12-092025-10-14
Autologous Transplant To End NMO Spectrum Disorder
Rituximab, Cyclophosphamide, Mesna - Neuromyelitis Optica, Devic's Disease
Phase 2 / Phase 3WithdrawnNorthwestern University2019-11-012019-11-20
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
Placebo, RC18 160 mg - Neuromyelitis Optica Spectrum Disorders
Phase 3TerminatedRemeGen Co., Ltd.1782018-01-292026-04-13
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
Tocilizumab Injection, Azathioprine - Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica
Phase 2 / Phase 3CompletedTianjin Medical University General Hospital1182017-11-012019-10-24
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
Azathioprine, Rituximab - Neuromyelitis Optica Spectrum Disorder
Phase 2 / Phase 3CompletedIsfahan University of Medical Sciences862015-09-012020-09-30
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Inebilizumab, Placebo - Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Phase 2 / Phase 3CompletedMedImmune LLC2312015-04-012021-12-03
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
Intravenous Methylprednisolone, Intravenous Immunoglobulin - Myelitis, Transverse, Neuromyelitis Optica
Phase 3TerminatedGuy's and St Thomas' NHS Foundation Trust22015-03-012016-07-20

Showing 20 of 25. Sign in to see all of them.

Narrower conditions

Myelitis, Transverse (6)  ·  Optic Neuritis (6)  ·  Demyelinating Diseases (5)  ·  Recurrence (4)  ·  Diffuse Cerebral Sclerosis of Schilder (1)  ·  Encephalomyelitis, Acute Disseminated (1)  ·  Mental Disorders (1)  ·  Multiple Sclerosis (1)  ·  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (1)  ·  Myelitis (1)  ·  Neurologic Manifestations (1)  ·  Rare Diseases (1)

Broader conditions

Autoimmune Diseases (25)  ·  Autoimmune Diseases of the Nervous System (25)  ·  Cranial Nerve Diseases (25)  ·  Demyelinating Autoimmune Diseases, CNS (25)  ·  Eye Diseases (25)  ·  Immune System Diseases (25)  ·  Nervous System Diseases (25)  ·  Optic Nerve Diseases (25)  ·  Demyelinating Diseases (20)  ·  Myelitis, Transverse (19)  ·  Optic Neuritis (19)  ·  Central Nervous System Diseases (7)  ·  Central Nervous System Infections (7)  ·  Infections (7)  ·  Neuroinflammatory Diseases (7)

Interventions

Azathioprine (4)  ·  eculizumab (4)  ·  satralizumab (4)  ·  ravulizumab (3)  ·  Immunoglobulins, Intravenous (2)  ·  Plasma Exchange (2)  ·  Rituximab (2)  ·  inebilizumab (2)  ·  Adrenal Cortex Hormones (1)  ·  Antilymphocyte Serum (1)  ·  Cyclophosphamide (1)  ·  Filgrastim (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Immunoglobulin G (1)  ·  Mesna (1)

Sponsors

Alexion Pharmaceuticals, Inc. (7)  ·  Hoffmann-La Roche (4)  ·  Tianjin Medical University General Hospital (4)  ·  Beijing Mabworks Biotech Co., Ltd. (1)  ·  Biocad (1)  ·  Guy's and St Thomas' NHS Foundation Trust (1)  ·  Hospices Civils de Lyon (1)  ·  Isfahan University of Medical Sciences (1)  ·  MedImmune LLC (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  Northwestern University (1)  ·  RemeGen Co., Ltd. (1)  ·  Shanghai Jiaolian Drug Research and Development Co., Ltd (1)

Countries

United States (11)  ·  China (9)  ·  Italy (9)  ·  Japan (8)  ·  South Korea (8)  ·  Spain (8)  ·  Canada (7)  ·  Germany (7)  ·  United Kingdom (7)  ·  Poland (6)  ·  Taiwan (6)  ·  Turkey (Türkiye) (6)  ·  France (5)  ·  Australia (4)  ·  Croatia (4)

Top investigators

Brian G. Weinshenker (1)  ·  Fu-Dong Shi, MD,PhD (1)  ·  Ming Lim, MB, PhD (1)  ·  Richard Burt, MD (1)  ·  Vahid Shaygannejad, M.D. (1)  ·  Xiangjun Chen, M.D (1)

Results publications

PMID 40743487, PMID 33676197, PMID 34498507, PMID 36007339, PMID 36724181, PMID 40288333, PMID 26009577, PMID 26666258, PMID 28639937, PMID 28831548, PMID 31050279, PMID 31495497, PMID 31774956, PMID 32333897, PMID 32333898, PMID 33310418, PMID 33538237, PMID 33724534, PMID 33771837, PMID 34803867, PMID 35158461, PMID 36370634, PMID 37221052, PMID 38356884, PMID 38760098, PMID 39222408, PMID 41782198, PMID 42177718, PMID 42441931, PMID 42575985

NIH funding

2019 (3), 2014 (2), 2015 (1), 2023 (1)